Search results
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Benzinga via Yahoo Finance· 2 days agoGeneric and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on...
Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation
Morningstar· 2 days agoThe Swiss...t impact previously disclosed guidance for this year. Sandoz received U.S. Food and Drug Administration approval for Wyost and Jubbonti--the first denosumab biosimilars ...
Unveiling the role of hypoxia-inducible factor 2alpha in osteoporosis: Implications for bone health
Newswise· 6 days agoBACKGROUNDOsteoporosis (OP) has become a major public health problem worldwide. Most OP treatments are based on the inhibition of bone resorption, and it is nec
FDA Roundup: April 26, 2024
FOX21 Colorado Springs· 6 days agoThis represents the first FDA approval of a radioactive drug, or radiopharmaceutical, for pediatric patients 12 years of age and older with SSTR-positive GEP-NETs. Full...
Could delaying menopause boost women's health? 1 woman shares her story
TODAY via Yahoo News· 7 days agoA new study examines whether delaying menopause can help women's health, including reducing heart...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost
Council Post: AI Can ‘Unbias’ Healthcare—But Only If We Work Together To End Data Disparity
Forbes· 6 days agoThe excitement around AI’s potential to solve healthcare’s biggest problems is palpable. For anyone...
Story from Montefiore Einstein: Eliminate asthma attacks? The latest treatments for breathing easier
The Journal News· 3 days agoAnyone who’s ever suffered from asthma knows all too well that the usual symptoms — wheezing,...
UCB SA's Dividend Analysis
GuruFocus.com via Yahoo Finance· 7 days agoUCB SA (UCBJY) recently announced a dividend of $0.73 per share, payable on 2024-05-15, with the ex-dividend date set for 2024-04-26. As investors look...
So you’ve found research fraud. Now what?
Vox· 6 days agoAfter dishonesty researcher Francesca Gino was placed on leave at Harvard Business School last fall following allegations that four of her papers...
